GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Cash Flow from Discontinued Operations

Pharmala Biotech Holdings (XCNQ:MDMA) Cash Flow from Discontinued Operations : C$0.00 Mil (TTM As of Feb. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Pharmala Biotech Holdings's cash flow from discontinued operations for the three months ended in Feb. 2025 was C$0.00 Mil. It means Pharmala Biotech Holdings received C$0.00 Mil from the sale of part of business quarterly. Pharmala Biotech Holdings's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Feb. 2025 was C$0.00 Mil.


Pharmala Biotech Holdings Cash Flow from Discontinued Operations Historical Data

The historical data trend for Pharmala Biotech Holdings's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Cash Flow from Discontinued Operations Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Cash Flow from Discontinued Operations
- - - -

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24 Feb25
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmala Biotech Holdings Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmala Biotech Holdings Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Industry
Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.
Executives
Fraser Macdonald Director
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines